株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

体外毒性検査の世界市場:2019年~2023年

In-vitro Toxicity Testing Market by End-users and Geography - Global Forecast and Analysis 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 910709
出版日 ページ情報 英文 148 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
体外毒性検査の世界市場:2019年~2023年 In-vitro Toxicity Testing Market by End-users and Geography - Global Forecast and Analysis 2019-2023
出版日: 2019年09月09日 ページ情報: 英文 148 Pages
概要

世界の体外毒性検査市場は、企業による体外毒性検査の増加で薬物障害の低減、有毒物質の存在、意識向上プログラムなどが市場成長要因となり、予測期間中に7%のCAGRで拡大する見込みです。ただし、前臨床検査の限界、限られた数の熟練した専門家、厳しい規制の存在などの課題が、予測期間中の体外毒性検査業界の成長を妨げる可能性があります。

当レポートでは、世界の体外毒性検査市場について調査分析し、市場規模および成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:エンドユーザー別

  • 市場セグメンテーション:エンドユーザー別
  • エンドユーザー別比較:市場規模および予測(2018年~2023年)
  • 製薬およびバイオテクノロジー企業
  • 学術研究機関
  • その他
  • 市場機会:エンドユーザー別

第7章 顧客情勢

第8章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

  • 毒物学の進歩
  • 化粧品需要の急増
  • 創薬への投資の増加

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • CELTHER POLSKA Sp z oo
  • Charles River Laboratories International Inc.
  • Eurofins GSC Lux Sarl
  • Evotec AG
  • General Electric Co.
  • Merck KGaA
  • Thermo Fisher Scientific Inc.

第14章 付録

  • 調査方法
  • 略語のリスト
  • ベンダーの市場ポジショニングの定義

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31998

About this Market

In-vitro toxicity testing is designed to identify toxic components in biological samples. Technavio's in-vitro toxicity testing market analysis considers sales to the pharmaceutical and biotechnology companies, academic and research institutions, and others. Our analysis also considers the provision of in-vitro toxicity testing in Asia, Europe, North America, and ROW. In 2018, the pharmaceutical and biotechnology companies segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as increasing costs of developing new drugs, rising number of drug rejection cases, and long duration required to get drug approval are prompting pharmaceutical and biotechnology companies to opt for in-vitro toxicity testing of drugs. As a result, the segment will maintain its leading market position over the forecast period. Also, our global in-vitro toxicity testing report has observed market growth factors such as increasing use of in-vitro toxicity testing by companies to reduce drug failures, presence of toxic substances, and rising number of awareness programs. However, challenges such as limitations of preclinical studies, a limited number of skilled professionals, and presence of stringent regulations may hamper the growth of the in-vitro toxicity testing industry over the forecast period.

Overview

Increasing use of in-vitro toxicity testing by companies to reduce drug failures

In-vitro toxicity testing is essential for pharmaceutical companies, as the technique will allow them to reduce the rejection rate of drugs in the last development stage and save cost. The testing is crucial to eliminate toxic effects in drugs that will enhance patient compliance, which, in turn, will increase sales of drugs. As a result, the demand for in-vitro toxicity testing kits and devices will increase. Consequently, the in-vitro toxicity testing market is expected to record a CAGR of almost 7% during 2019-2023.

Advances in toxicology

Constant advances in the field of toxicology, which is one of the key market trends, are prompting vendors to improve and innovate their products. The field of toxicology has been recording various technological advances such as cell culture technologies, cellular imaging technologies, and toxicogenomic. Vendors have come up with advanced techniques such as in-silico techniques that can identify smaller toxic molecular compounds. Moreover, these techniques do not require biological samples and function on computer simulation, reducing operational cost for end-users. These factors will have a positive impact on the in-vitro toxicity testing market during the forecast period.

For the detailed list of factors that will drive the global in-vitro toxicity testing market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global in-vitro toxicity testing market is concentrated. Technavio's robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of few leading vendors such as Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., CELTHER POLSKA Sp z o.o., Charles River Laboratories International Inc., Eurofins GSC Lux Sarl, Evotec AG, General Electric Co., Merck KGaA, and Thermo Fisher Scientific Inc.

Also, the in-vitro toxicity testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies in strategizing and leveraging on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY END-USER

  • Market segmentation by end-user
  • Comparison by end-user
  • Pharmaceutical and biotechnology companies -
  • Market size and forecast 2018-2023
  • Academic and research institutions - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by end-user

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Advances in toxicology
  • Surge in demand for cosmetics
  • Increasing investments in drug discovery

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • CELTHER POLSKA Sp z o.o.
  • Charles River Laboratories International Inc.
  • Eurofins GSC Lux Sarl
  • Evotec AG
  • General Electric Co.
  • Merck KGaA
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global healthcare market
  • Exhibit 03: Segments of global healthcare market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: End-user - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by end-user
  • Exhibit 20: Pharmaceutical and biotechnology companies - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Pharmaceutical and biotechnology companies - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Academic and research institutions - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Academic and research institutions - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by end-user
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Impact of drivers and challenges
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: Abbott Laboratories - Vendor overview
  • Exhibit 47: Abbott Laboratories - Business segments
  • Exhibit 48: Abbott Laboratories - Organizational developments
  • Exhibit 49: Abbott Laboratories - Geographic focus
  • Exhibit 50: Abbott Laboratories - Segment focus
  • Exhibit 51: Abbott Laboratories - Key offerings
  • Exhibit 52: Agilent Technologies Inc. - Vendor overview
  • Exhibit 53: Agilent Technologies Inc. - Business segments
  • Exhibit 54: Agilent Technologies Inc. - Organizational developments
  • Exhibit 55: Agilent Technologies Inc. - Geographic focus
  • Exhibit 56: Agilent Technologies Inc. - Segment focus
  • Exhibit 57: Agilent Technologies Inc. - Key offerings
  • Exhibit 58: Bio-Rad Laboratories Inc. - Vendor overview
  • Exhibit 59: Bio-Rad Laboratories Inc. - Business segments
  • Exhibit 60: Bio-Rad Laboratories Inc. - Organizational developments
  • Exhibit 61: Bio-Rad Laboratories Inc. - Geographic focus
  • Exhibit 62: Bio-Rad Laboratories Inc. - Segment focus
  • Exhibit 63: Bio-Rad Laboratories Inc. - Key offerings
  • Exhibit 64: CELTHER POLSKA Sp z o.o. - Vendor overview
  • Exhibit 65: CELTHER POLSKA Sp z o.o. - Business segments
  • Exhibit 66: CELTHER POLSKA Sp z o.o. - Organizational developments
  • Exhibit 67: CELTHER POLSKA Sp z o.o. - Key offerings
  • Exhibit 68: Charles River Laboratories International Inc. - Vendor overview
  • Exhibit 69: Charles River Laboratories International Inc. - Business segments
  • Exhibit 70: Charles River Laboratories International Inc. - Organizational developments
  • Exhibit 71: Charles River Laboratories International Inc. - Geographic focus
  • Exhibit 72: Charles River Laboratories International Inc. - Segment focus
  • Exhibit 73: Charles River Laboratories International Inc. - Key offerings
  • Exhibit 74: Eurofins GSC Lux Sarl - Vendor overview
  • Exhibit 75: Eurofins GSC Lux Sarl - Business segments
  • Exhibit 76: Eurofins GSC Lux Sarl - Organizational developments
  • Exhibit 77: Eurofins GSC Lux Sarl - Geographic focus
  • Exhibit 78: Eurofins GSC Lux Sarl - Segment focus
  • Exhibit 79: Eurofins GSC Lux Sarl - Key offerings
  • Exhibit 80: Evotec AG - Vendor overview
  • Exhibit 81: Evotec AG - Business segments
  • Exhibit 82: Evotec AG - Organizational developments
  • Exhibit 83: Evotec AG - Geographic focus
  • Exhibit 84: Evotec AG - Segment focus
  • Exhibit 85: Evotec AG - Key offerings
  • Exhibit 86: General Electric Co. - Vendor overview
  • Exhibit 87: General Electric Co. - Business segments
  • Exhibit 88: General Electric Co. - Organizational developments
  • Exhibit 89: General Electric Co. - Geographic focus
  • Exhibit 90: General Electric Co. - Segment focus
  • Exhibit 91: General Electric Co. - Key offerings
  • Exhibit 92: Merck KGaA - Vendor overview
  • Exhibit 93: Merck KGaA - Business segments
  • Exhibit 94: Merck KGaA - Organizational developments
  • Exhibit 95: Merck KGaA - Geographic focus
  • Exhibit 96: Merck KGaA - Segment focus
  • Exhibit 97: Merck KGaA - Key offerings
  • Exhibit 98: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 99: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 100: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 101: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 102: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 103: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 104: Validation techniques employed for market sizing
  • Exhibit 105: Definition of market positioning of vendors
Back to Top